Swiss biotech Secures $152 Million in Latest Series B Funding Round

Swiss biotech secured $152 million in its latest Series B, adding another data point to the Healthcare & Life Sciences funding market.

Swiss biotech Raises $152 million in Funding

Bernhard completes long-delayed utilities acquisition; Swiss biotech raises $152m Series B.

Investors Behind the Funding

The round was backed by China 3698. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Swiss biotech operates in Healthcare & Life Sciences. Swiss biotech's financing adds to recent private-market activity.

Strategic Use of Funds

Francisco Partners awaits regulatory sign-off Canadian payments pioneer Moneris’ $1.

Looking Ahead

Bernhard completes long-delayed utilities acquisition; Swiss biotech raises $152m Series B

Source reference: original announcement/article.